Henry James International Management Inc. Sells 13,512 Shares of Astrazeneca Plc $AZN

Henry James International Management Inc. lessened its stake in shares of Astrazeneca Plc (NYSE:AZN) by 36.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,140 shares of the company’s stock after selling 13,512 shares during the quarter. Astrazeneca comprises 1.1% of Henry James International Management Inc.’s investment portfolio, making the stock its 29th biggest holding. Henry James International Management Inc.’s holdings in Astrazeneca were worth $3,736,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently made changes to their positions in AZN. Mascoma Wealth Management LLC acquired a new position in Astrazeneca during the 1st quarter worth approximately $26,000. MV Capital Management Inc. acquired a new position in shares of Astrazeneca during the fourth quarter worth approximately $26,000. Roxbury Financial LLC acquired a new position in shares of Astrazeneca during the second quarter worth approximately $29,000. Reflection Asset Management bought a new position in shares of Astrazeneca in the 4th quarter worth $31,000. Finally, Resources Management Corp CT ADV bought a new position in shares of Astrazeneca in the 1st quarter worth $35,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca Stock Performance

AZN traded up $6.58 during trading on Wednesday, hitting $162.40. 1,452,581 shares of the company traded hands, compared to its average volume of 2,793,238. The stock’s fifty day moving average is $161.95 and its 200 day moving average is $176.56. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. Astrazeneca Plc has a one year low of $153.41 and a one year high of $212.71. The firm has a market cap of $251.87 billion, a P/E ratio of 24.28, a price-to-earnings-growth ratio of 1.34 and a beta of 0.27.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.13. The business had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%. Astrazeneca’s revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.17 earnings per share. As a group, equities analysts predict that Astrazeneca Plc will post 9.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on AZN shares. Zacks Research cut shares of Astrazeneca from a “hold” rating to a “strong sell” rating in a report on Monday, September 14th. Bank of America reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Weiss Ratings lowered shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, July 28th. Citigroup reiterated a “buy” rating on shares of Astrazeneca in a report on Tuesday, October 6th. Finally, Wall Street Zen downgraded shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Sunday. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus target price of $206.67.

Astrazeneca Company Profile

AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. Its research, development and commercial operations focus on prescription medicines for serious and chronic diseases, with an emphasis on discovering and delivering innovative therapies rather than operating as a diversified healthcare conglomerate.

The company’s principal therapeutic areas include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunological conditions; and rare diseases.